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Background: Autonomic imbalance namely high sympathetic and low parasympathetic drive is a feature of chronic heart failure (HF). Therapy 
with beta-blockers partly restores autonomic balance and, in doing so, slows HF progression. This study tested the hypothesis that Vagus nerve 
stimulation (VS) prevents the progression of HF.
Methods: Studies were performed in 15 dogs with moderate HF (LV ejection fraction, EF 30%-40%) produced by coronary microembolizations. All 
dogs underwent surgical implantation of a bipolar cuff electrode around the right Vagus nerve connected to an implantable pulse generator. Dogs 
were then randomized to no therapy (control, n=7) or to active VS therapy (n=8) maintained for 3 months. Active VS was delivered for 10 sec of every 
minute. The stimulation parameters were 20Hz, 0.3 ms pulse width and 1.5 to 2.0 mA. LV end-diastolic (EDV) and end-systolic (ESV) volumes and EF 
were measured from ventriculograms taken at time of randomization (PRE) and after 3 months of therapy (POST).
Results: There were no significant adverse side effects to VS. In controls, EDV and ESV increased and EF decreased significantly. In VS-treated dogs, 
EDV was unchanged, ESV decreased and EF increased significantly (Table).
Conclusions: Long-term VS therapy improves LV function and prevents progressive LV dilation in dogs with moderate HF. The results support the 
potential use of VS therapy as an adjunct to the treatment regimen of patients with chronic HF. 
PRE POST
Control VS Control VS
EDV (ml) 60.6 ± 1.9 60.6 ± 1.7 63.0 ±1.7 61.0 ± 1.7
ESV (ml) 39.3 ± 1.6 39.4 ± 1.1 43.0 ± 1.5 35.9 ± 1.6*
EF (%) 35.0 ± 1.1 33.6 ± 0.7 31.7 ±1.1 40.1 ± 0.9*
*=p<0.05 vs. Control
